Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Phase 2
58
about 6 years
18+
2 sites in MN, WI
What this study is about
This trial is testing a new treatment approach for advanced gastric cancer. Patients will receive pembrolizumab, ramucirumab, and paclitaxel as part of the treatment regimen. It involves two segments: an induction immunotherapy segment with pembrolizumab monotherapy followed by a combination therapy segment.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Paclitaxel
- 2.Take Pembrolizumab Monotherapy
- 3.Take Ramucirumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
paclitaxel (Taxane chemotherapy; stabilizes microtubules), immunotherapy (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer), ramucirumab
injection, intravenous, infusion, injection (Injection)
Primary: Cohort 1: Evaluate the best overall response rate (BORR) by pooling Arm A and Arm B, Cohort 2: Evaluate Progression free survival (PFS) of Ramucirumab (RAM) plus Paclitaxel plus Pembrolizumab (PEM)
Secondary: Assess the frequency and severity of adverse events